This article is more than 5 years old. Information may no longer be current.

VIDEO: Santen initiates phase 3 studies of omidenepag for glaucoma

Issue: December 10, 2018

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — At the American Academy of Ophthalmology meeting here, Ellie Chabi, MD, the therapeutic area head for glaucoma and neuroprotection and the lead for artificial intelligence programs within global biomedical science at Santen, discusses the initiation of two phase 3 clinical trials of omidenepag isopropyl for the treatment of glaucoma and ocular hypertension.